Compared to Estimates, Integer (ITGR) Q4 Earnings: A Look at Key Metrics
Integer (ITGR) reported $413.15 million in revenue for the quarter ended December 2023, representing a year-over-year increase of 10.9%. EPS of $1.39 for the same period compares to $1.11 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $412.05 million, representing a surprise of +0.27%. The company delivered an EPS surprise of +3.73%, with the consensus EPS estimate being $1.34.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Integer performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- Non-Medical: $9.09 million compared to the $13.88 million average estimate based on three analysts. The reported number represents a change of -41.9% year over year.
- Revenue- Total Medical Sales: $413.15 million compared to the $394.44 million average estimate based on three analysts.
- Revenue- IMC - Advanced Surgical, Orthopedics & Portable Medical: $28.61 million versus the three-analyst average estimate of $25.74 million. The reported number represents a year-over-year change of +0.8%.
- Revenue- IMC - Cardio & Vascular: $222.64 million versus the three-analyst average estimate of $206.57 million. The reported number represents a year-over-year change of +19.9%.
- Revenue- IMC - Cardiac Rhythm Management & Neuromodulation: $152.81 million compared to the $162.13 million average estimate based on three analysts. The reported number represents a change of +7.1% year over year.
Shares of Integer have returned +1% over the past month versus the Zacks S&P 500 composite's +4.6% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s credited with a “watershed medical breakthrough” and is developing a bustling pipeline of other projects that could make a world of difference for patients suffering from diseases involving the liver, lungs, and blood. This is a timely investment that you can catch while it emerges from its bear market lows.
It could rival or surpass other recent Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock And 4 Runners UpInteger Holdings Corporation (ITGR) : Free Stock Analysis Report
